A Randomised Double Blind, Multiple Dose, Pharmacokinetic and Safety Study of SENS 401 in Healthy Subjects

Trial Profile

A Randomised Double Blind, Multiple Dose, Pharmacokinetic and Safety Study of SENS 401 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs R-azasetron-besylate (Primary)
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Oct 2017 Status changed from active, no longer recruiting to completed, according to a Sensorion media release.
    • 09 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top